Acetazolamide and thiamine: an ancillary therapy for chronic mental illness.
Twenty-four chronic schizophrenic patients were treated successfully with the addition of acetazolamide and thiamine (A + T) to their unchanged existing therapies in a double-blind, placebo-controlled crossover study. Therapeutic effects were measured by the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Negative Symptoms. Overall, 50% of the patients showed improvement on all assessment scales. No untoward effects occurred in these patients or in patients in previous studies who have been treated continuously with A + T therapy for as long as 3 years.
Sacks
W
W
Cerebral Metabolism Laboratory, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962.
Esser
A H
AH
Feitel
B
B
Abbott
K
K
D000086:Acetazolamide / Q000008:administration & dosage*; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013831:Thiamine / Q000008:administration & dosage*
D001786:Blood Glucose; D000086:Acetazolamide; D013831:Thiamine